Pazopanib tedavisi alan yumuşak doku sarkomlu hastalarda sağkalım sonuçları: tek merkez deneyimi

Yıl 2025, Cilt: 50 Sayı: 4, 1135 - 1144, 22.12.2025

Mert Tohumcuoğlu , Mahmut Büyükşimşek

https://doi.org/10.17826/cumj.1803102

https://izlik.org/JA48HY84PR

Öz

Amaç: Bu çalışmada ileri evre yumuşak doku sarkomu tanısıyla pazopanib alan hastalardan oluşan tek merkezli retrospektif kohortta genel sağkalım (OS) ve progresyonsuz sağkalımın (PFS) değerlendirilmesi ve klinikopatolojik alt gruplar arasında sonuçların karşılaştırılması amaçlandı.
Gereç ve Yöntem: Çalışmamızda, Mart 2020–Aralık 2024 döneminde pazopanib başlanan, lokal ileri ve metastatik non-adipositik yumuşak doku sarkomu tanılı 45 erişkin hastadan oluşan tek merkezli retrospektif bir kohort incelendi. Klinik, patoloji, görüntüleme, tedavi ve takip verileri kurumun elektronik kayıtlarından elde edildi. Genel sağkalım (OS) pazopanib başlangıcından ölüme kadar, progresyonsuz sağkalım (PFS) ise pazopanib başlangıcından progresyon veya ölüme kadar geçen süre olarak tanımlandı. Sağkalım analizleri %95 güven aralıklarıyla Kaplan–Meier yöntemiyle yapıldı.
Bulgular: Toplam 45 hasta analiz edildi. Medyan PFS 4,50 ay (%95 GA, 2,28–10,26) ve medyan OS 6,90 ay (%95 GA, 2,85–17,36) bulundu; 1 yıllık OS %35,6 idi. İzlem süresince progresyon oranı %82,2, ölüm oranı %73,3’tü. Önceden tanımlı alt gruplarda PFS benzerdi ve OS için istatistiksel olarak anlamlı fark saptanmadı; Kaplan–Meier/log-rank karşılaştırmalarında radyoterapi öyküsü olanlarda OS sayısal olarak daha uzundu; bu grupta medyan OS 16,53 ay iken radyoterapi almayanlarda 6,90 ay idi.
Sonuç: Çalışmamızın verileri, pazopanibin faz III randomize çalışmada bildirilen etkinlik düzeyiyle uyumlu bir hastalık kontrolü sağladığını, buna karşın başlangıçtaki risk profili ve pazopanib sonrası uygulanan tedavilerin genel sağkalım üzerinde belirleyici olabileceğini düşündürmektedir; bu bulguların daha geniş, prospektif ve çok merkezli kohortlarda doğrulanması gerekmektedir.

Anahtar Kelimeler

Yumuşak Doku Sarkomu , Pazopanib , Sağkalım Sonuçları

Pazopanib and survival outcomes in soft-tissue sarcoma: a single-center experience

https://izlik.org/JA48HY84PR

Öz

Purpose: The aim of this study was to evaluate overall and progression-free survival and explore subgroup differences in a single-center retrospective cohort of patients with advanced soft-tissue sarcoma receiving pazopanib.
Materials and Methods: A single-center retrospective cohort study included 45 adults with locally advanced or metastatic non-adipocytic soft-tissue sarcoma who initiated pazopanib between March 2020 and December 2024. Data were extracted from institutional electronic records (pathology, imaging, treatment, and follow-up). Overall survival (OS; from pazopanib initiation to death) and progression-free survival (PFS; from initiation to disease progression or death) were estimated using the Kaplan–Meier method with 95% confidence intervals.
Results: Forty-five patients were analyzed. Median PFS was 4.50 months (95% CI, 2.28–10.26) and median OS was 6.90 months (95% CI, 2.85–17.36); 1-year OS was 35.6%. Event rates were 82.2% for progression and 73.3% for death during follow-up. No subgroup differences reached significance for either PFS or OS; in Kaplan–Meier/log-rank comparisons, OS was numerically longer in patients with prior radiotherapy (16.53 vs 6.90 months).
Conclusion: These real-world data suggest that pazopanib maintains disease control consistent with the efficacy reported in the phase III randomized trial, whereas baseline risk profile and subsequent therapies are likely to influence overall survival; these findings should be confirmed in larger prospective multicenter cohorts.

Anahtar Kelimeler

Soft-Tissue Sarcoma , Pazopanib , Survival Outcomes

Kaynakça

• Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353:701-11.
• Casali PG, Blay JY; Esmo/Conticanet/Eurobonet Consensus Panel of Experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v198-203.
• WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours. WHO Classification of Tumours. 5th ed. Vol 3. Lyon (France): International Agency for Research on Cancer; 2020.
• Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003;97:2530-43.
• Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere-Vince D et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91:1914-26.
• Hoven-Gondrie ML, Bastiaannet E, Ho VKY, van Leeuwen BL, Liefers GJ, Hoekstra HJ et al. Worse survival in elderly patients with extremity soft-tissue sarcoma. Ann Surg Oncol. 2016;23:2577-85.
• Crago AM, Brennan MF. Principles in management of soft tissue sarcoma. Adv Surg. 2015;49:107-22.
• Koliou P, Karavasilis V, Theochari M, Pollack SM, Jones RL, Thway K. Advances in the treatment of soft tissue sarcoma: focus on eribulin. Cancer Manag Res. 2018;10:207-16.
• Ayodele O, Abdul Razak AR. Immunotherapy in soft-tissue sarcoma. Curr Oncol. 2020;27(Suppl 1):17-23.
• Heudel P, Cassier P, Derbel O, Dufresne A, Meeus P, Thiesse P et al. Pazopanib for the treatment of soft-tissue sarcoma. Clin Pharmacol. 2012;4:65-70.
• van der Graaf WTA, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879-86.
• Bilici A, Koca S, Karaagac M, Goktas Aydin S, Eraslan E, Kaplan MA et al. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study. J Cancer Res Clin Oncol. 2023;149:8243-53.
• Pehlivan M, Basaran M, Ekenel M. Pazopanib treatment in soft tissue sarcoma (single center experience). Eurasian J Med Investig. 2023;7:494-500.
• Karhan O, Ileri S, Yerlikaya H, Urun M, Sezgin Y. Real-life data of pazopanib usage in soft tissue sarcoma. Turk J Clin Lab. 2023;14:274-9.
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 1.2025. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2025.
• Radaelli S, Merlini A, Khan M, Gronchi A. Progress in histology specific treatments in soft tissue sarcoma. Expert Rev Anticancer Ther. 2024;24:845-68.
• Mirili C, Paydas S, Guney IB, Ogul A, Gokcay S, Buyuksimsek M et al. Assessment of potential predictive value of peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective study. Cancer Manag Res. 2019;11:3445-53.